SUPN Q2 2019 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$105M+5.2% YoY

Gross Profit

$101M96.1% margin

Operating Income

$43M40.7% margin

Net Income

$33M31.3% margin

EPS (Diluted)

$0.61

QoQ Revenue Growth

+22.5%

Cash Flow

Operating Cash Flow

$29M

Free Cash Flow

$29M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$541M

Stockholders' Equity

$523M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$105M	$100M	+5.2%
Gross Profit	$101M	$96M	+5.0%
Operating Income	$43M	$36M	+19.3%
Net Income	$33M	$31M	+6.5%